The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is
leading a consortium of organizations, including European medicines
regulators, academics, and the pharmaceutical industry in a three-year
project to develop new ways of gathering information on suspected
adverse drug reactions (ADRs). The project, known as WEB-RADR, is in response to the rapid adoption of
smartphones, apps, and social media for discussing issues with medicines
It will work to develop a mobile app for healthcare professionals and
the public to report suspected ADRs to national EU regulators. It will
also investigate the potential for publicly available social media data
for identifying potential drug-safety issues. All social media data used
within the project will be appropriately anonymized to protect data
In addition to reporting suspected ADRs the app could also serve as a
platform to send accurate, timely, and up-to-date medicines information
to patients, clinicians, and caregivers.
WEB-RADR will also examine the value of these new tools for monitoring
drug safety. It will help to develop recommendations for medicines
regulators and the pharmaceutical industry internationally on how these
should be used alongside existing systems.
This project is funded though the Innovative Medicines Initiative, a
public/private partnership between the European Commission and European
Federation of Pharmaceutical Industries and Associations.